drugset / Trial / NCT06561542
A Phase I Study of LX22001 for Injection in Healthy Subjects
Non-randomizedParallel-groupOpen-labelBasic science
Summary
Study to evaluate the safety and tolerability, pharmacokinetics/pharmacodynamics (PK/PD) parameters of an escalating, single dose/repeat doses of LX22001 for injection in healthy subjects.
Timeline
- Start
- 2024-08-05
- Primary completion
- 2025-11-21
- Completion
- 2025-11-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Esomeprazole | Small molecule | 8 mg | Intravenous |
| Subject | LX22001 | Unknown | 25 mg | Intravenous |
| Subject | LX22001 | Unknown | 50 mg | Intravenous |
| Subject | LX22001 | Unknown | 100 mg | Intravenous |
| Subject | LX22001 | Unknown | 200 mg | Intravenous |
| Comparator | Tegoprazan | Other / unclassified | 50 mg | Oral |
Indications
No indication recorded.